Journal
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
Volume 88, Issue 2, Pages 188-191Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.diagmicrobio.2017.03.006
Keywords
Apramycin; Aminoglycoside; Activity spectrum; Acinetobacter; Pseudomonas aeruginosa; Repurposing
Categories
Funding
- Chief Academic Officer's Pilot Grant from Beth Israel Deaconess Medical Center
- Long Term Health Education and Training Program from the US. Army Medical Department Center and School at Fort Sam Houston, TX
Ask authors/readers for more resources
The in vitro activity of apramycin was compared to that of amikacin, gentamicin, and tobramycin against multidrug-resistant, extensively drug-resistant, and pandrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Apramycin demonstrated an MIC50/MIC90 of 8/32 mu g/ml for A. baumannii and 16/32 mu g/ml for P. aeruginosa. Only 2% of A. baumannii and P. aeruginosa had an MIC greater than an epidemiological cutoff value of 64 mu g/ml. In contrast, the MIC50/MIC90 for amikacin, gentamicin, and tobramycin were >= 64/>256 mu g/ml for A. baumannii with 57%, 95%, and 74% of isolates demonstrating resistance, respectively, and the MIC50/ MIC90 were >= 8/256 mu g/ml for P. aeruginosa with 27%, 50%, and 57% of strains demonstrating resistance, respectively. Apramycin appears to offer promising in vitro activity against highly resistant pathogens. It therefore may warrant further pre-clinical study to assess potential for repurposing as a human therapeutic and relevance as a scaffold for further medicinal chemistry exploration. (C) 2017 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available